JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 102 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,075 | +250.2% | 581,300 | +109.9% | 0.00% | – |
| Q4 2022 | $307 | -99.8% | 276,896 | +247.4% | 0.00% | – |
| Q3 2022 | $186,000 | -70.9% | 79,700 | -62.2% | 0.00% | -100.0% |
| Q2 2022 | $640,000 | +420.3% | 211,081 | +1066.2% | 0.00% | – |
| Q1 2022 | $123,000 | -86.4% | 18,100 | -86.4% | 0.00% | -100.0% |
| Q2 2021 | $906,000 | +357.6% | 133,300 | +590.3% | 0.00% | – |
| Q1 2021 | $198,000 | -78.3% | 19,310 | -85.2% | 0.00% | -100.0% |
| Q4 2020 | $914,000 | -62.7% | 130,514 | -56.5% | 0.00% | -50.0% |
| Q3 2020 | $2,449,000 | -28.5% | 300,114 | -39.6% | 0.00% | -33.3% |
| Q2 2020 | $3,427,000 | +3.0% | 496,614 | -29.1% | 0.00% | 0.0% |
| Q1 2020 | $3,326,000 | -7.1% | 700,114 | +70.8% | 0.00% | 0.0% |
| Q4 2019 | $3,579,000 | +2095.7% | 409,914 | +738.1% | 0.00% | – |
| Q3 2019 | $163,000 | +186.0% | 48,908 | +321.6% | 0.00% | – |
| Q2 2019 | $57,000 | -27.8% | 11,600 | -9.4% | 0.00% | – |
| Q1 2019 | $79,000 | -88.9% | 12,800 | -94.0% | 0.00% | -100.0% |
| Q4 2018 | $714,000 | -34.3% | 212,000 | +26.9% | 0.00% | 0.0% |
| Q3 2018 | $1,086,000 | – | 167,047 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
| TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
| COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
| Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
| Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
| PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
| RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
| Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
| Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |